Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicity.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. Targeting nucleocytoplasmic transport in cancer therapy.Oncotarget · 2014
   Review
2. Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53.Cell cycle (Georgetown, Tex.) · 2013
   Article
3. p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3.Cell cycle (Georgetown, Tex.) · 2012
   Article
4. Tissue-specific expression of p73 C-terminal isoforms in mice.Cell cycle (Georgetown, Tex.) · 2012
   Article
5. Recent discoveries in the cycling, growing and aging of the p53 field.Aging · 2012
   Review
6. Advances in targeting signal transduction pathways.Oncotarget · 2012
   Review
7. Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions.Oncotarget · 2012
   Article
8. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Oncotarget · 2012
   Review
9. Cyclotherapy: opening a therapeutic window in cancer treatment.Oncotarget · 2012
   Article
10. Re-oxygenation causes hypoxic tumor regression through restoration of p53 wild-type conformation and post-translational modifications.Cell death & disease · 2012
    Article
11. Phospho-ΔNp63α/miR-885-3p axis in tumor cell life and cell death upon cisplatin exposure.Cell cycle (Georgetown, Tex.) · 2011
    Article
12. Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells.Oncotarget · 2011
    Article
13. Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy.Oncotarget · 2011
    Article

Corrections and comments

• Comment on
  Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture.2011

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as